Daré Bioscience Announces Publication In The Journal Of Sexual Medicine, Safety Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Daré Bioscience Announces Publication In The Journal Of Sexual Medicine, Safety Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences.
公布的数据显示，3.6%局部Sildenafil Cream在1,357次性体验中对女性和她们的伴侣是安全且耐受的。
Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in women.
使用3.6%局部Sildenafil Cream不会引起头痛和面部潮红等与口服Sildenafil相关的常见副作用。
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today announced that safety and tolerability data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder (FSAD), has been published by The Journal of Sexual Medicine.
2024年8月26日，加州圣地亚哥（环球新闻社），Daré Bioscience, Inc.（纳斯达克：DARE）宣布，作为女性健康和福祉创新领域的领导者，今日宣布了Sildenafil Cream 3.6%在女性性唤起障碍（FSAD）的临床探索性20亿RESPOND研究中的安全性和耐受性数据已由《性医学杂志》发表。